Mastocytosis Clinical Trial
Official title:
Low Intensity Preparative Regimen Followed by HLA-Matched, Mobilized Peripheral Blood Stem Cell Transplantation for Systemic Mastocytosis
This study will investigate the safety and effectiveness of an experimental stem cell
transplant procedure for treating mastocytosis-a disease of abnormal mast cell growth.
Patients often feel faint, have skin problems, joint and bone pain, low blood counts and
enlarged liver, spleen or lymph nodes. As yet, there is no cure for mastocytosis, and
treatment is aimed at controlling symptoms.
Stem cells are cells produced by the bone marrow that mature into the different blood
components-white cells, red cells and platelets. Transplantation of allogeneic (donated) stem
cells is a mainstay of therapy for some forms of leukemia. Patients first receive intensive
chemotherapy and radiation to rid the body of cancer cells. This "conditioning" is followed
by transplantation of donated stem cells to generate new, healthy bone marrow. In addition to
producing the new bone marrow, the donated cells also fight any residual tumor cells that
might have remained in the body. This is called a "graft-versus-tumor" effect. This study
will examine whether a stem cell transplant from a healthy donor can similarly target and
destroy mast cells in a "graft-versus-mast cell" effect. Also, to try to reduce the harmful
side effects of chemotherapy and radiation, this study will use lower dose chemotherapy and
no radiation.
Patients with advanced mastocytosis between 10 and 80 years old may be eligible for this
study. They will be
tested for HLA type matching with a sibling and will undergo a medical history, physical
examination and several tests to determine eligibility for the study.
Participants will undergo apheresis to collect lymphocytes (a type of white blood cell) for
immune function tests. In this procedure, blood is drawn through a needle in the arm, similar
to donating a unit of blood. The lymphocytes are then separated and collected by a cell
separator machine, and the rest of the blood is returned through a needle in the other arm.
Patients will also have a central venous line (flexible plastic tube) placed in their upper
chest leading to a vein. This line will remain in place throughout the transplant and
recovery period and will be used to transfuse blood components, administer medicines, infuse
the donated stem cells, and draw blood for tests. Patients will begin conditioning with
cyclophosphamide, starting 7 days before the transplant, and fludarabine, starting 5 days
before the transplant, to prevent rejection of the donated cells. From 1 to 3 days after the
chemotherapy is completed, the stem cells will be transfused through the central venous line.
Also, from 4 days before the transplantation until about 3 months after the procedure,
patients will receive cyclosporine and mycophenolate mofetil-drugs that help prevent both
rejection of the donated cells and attack by the donor cells on the patient's cells (called
graft-versus-host disease).
Patients will stay in the hospital about 20 to 30 days after the transplant. After discharge,
they will continue to take antibiotics, cyclosporine and mycophenolate mofetil at home. If
the mastocytosis progresses, cyclosporine and mycophenolate mofetil will be tapered over 4
weeks. If the mastocytosis persists, patients may receive additional transfusions of donor
lymphocytes to help kill the mast cells.
Patients' progress will be followed weekly or twice weekly for 3 months, then at 6, 12, 18,
24, 30, 36, 48 and 60 months after transplant, and then twice a year for various tests,
treatments and examinations.
Mastocytosis is a disease characterized by excessive numbers of mast cells in skin, bone
marrow and internal organs such as liver, spleen and lymph nodes. Its genesis appears to be
related to somatic mutations in c-kit, the receptor for mast cell growth factor. Although
most patients present with the indolent form of the disease, approximately one-third of the
patients have an associated hematologic disorder such as a myeloproliferative state or
myelodysplastic syndrome. Patients with advanced forms of the disease, including those with
an associated hematologic disorder have a poorer prognosis than those with indolent disease.
There is no treatment known to cure or improve the natural course of mastocytosis. Since mast
cells arise in the bone marrow from a CD34+ progenitor, bone marrow transplantation may offer
the only hope for a cure.
In this protocol, we propose to treat patients with advanced forms of mastocytosis with an
allogeneic stem cell transplant from an HLA-identical sibling, using a low intensity
non-myeloablative regimen. This approach has the advantage of decreasing the
transplant-related toxicity while allowing adequate immunosuppression to establish stem cell
and lymphocyte engraftment. Donor derived CD4 and CD8 lymphocytes, which are important in
killing of leukemic cells by mounting a "graft versus leukemia" effect, should be useful in
the elimination of aberrant mast cells and their progenitors, that is "graft-versus-mast cell
effect". This mechanism may be particularly relevant in mastocytosis as point mutations of
c-kit may constitute an antigenically distinct T-cell target for recognition by the engrafted
donor cells.
The primary end point of this study is regression of mastocytosis. The secondary end points
are engraftment, hematologic response, degree of donor-host chimerism, incidence and severity
of acute and chronic GVHD, transplant related morbidity and mortality, relapse, disease free
survival, and overall survival.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01333293 -
The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients
|
Phase 2/Phase 3 | |
Completed |
NCT01481909 -
Study on Mastocytosis for Rupatadine Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT00044122 -
Study of Factors Regulating Mast Cell Proliferation
|
||
Recruiting |
NCT06440148 -
Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis
|
||
Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
Not yet recruiting |
NCT05084872 -
Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients
|
Phase 2/Phase 3 | |
Terminated |
NCT01701843 -
Cromoglicate in Mastocytosis
|
Phase 2 | |
Completed |
NCT00831974 -
Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis
|
Phase 2 | |
Completed |
NCT00047918 -
Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing
|
N/A | |
Completed |
NCT00050193 -
Cause and Natural Course of Pediatric-Onset Mastocytosis
|
||
Completed |
NCT02620254 -
Mast Cell Connect: A Registry for Patients With Mastocytosis
|
||
Completed |
NCT00255346 -
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
|
Phase 2 | |
Completed |
NCT00001356 -
Characteristics of Mast Cells in Mastocytosis
|
N/A | |
Recruiting |
NCT06466889 -
Mastocytosis Registry (of Zurich)
|
||
Recruiting |
NCT05186753 -
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
|
Phase 2 | |
Completed |
NCT02478957 -
Treatment of Indolent Systemic Mastocytosis With PA101
|
Phase 2 | |
Recruiting |
NCT02450396 -
Pregnancy and Medically Assisted Conception in Rare Diseases
|
||
Completed |
NCT00038675 -
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
|
N/A | |
Not yet recruiting |
NCT06432556 -
Study of Cellular Heterogeneity in Patients With Mastocytosis
|
N/A | |
Completed |
NCT00336076 -
Molecular Mechanisms and Diagnosis of Mastocytosis
|
N/A |